Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Evaxion Biotech AS (EVAX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/16/2025: EVAX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $13.25
1 Year Target Price $13.25
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -78.3% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 15.48M USD | Price to earnings Ratio - | 1Y Target Price 13.25 |
Price to earnings Ratio - | 1Y Target Price 13.25 | ||
Volume (30-day avg) 2 | Beta 0.1 | 52 Weeks Range 1.20 - 17.75 | Updated Date 06/30/2025 |
52 Weeks Range 1.20 - 17.75 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -12 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -431.34% |
Management Effectiveness
Return on Assets (TTM) -37.07% | Return on Equity (TTM) -206.44% |
Valuation
Trailing PE - | Forward PE 3.57 | Enterprise Value 20461435 | Price to Sales(TTM) 4.7 |
Enterprise Value 20461435 | Price to Sales(TTM) 4.7 | ||
Enterprise Value to Revenue 6.21 | Enterprise Value to EBITDA -0.59 | Shares Outstanding 6316570 | Shares Floating 155104950 |
Shares Outstanding 6316570 | Shares Floating 155104950 | ||
Percent Insiders 23.07 | Percent Institutions 7.09 |
Analyst Ratings
Rating 2 | Target Price 13.25 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Evaxion Biotech AS
Company Overview
History and Background
Evaxion Biotech AS is a Danish clinical-stage biotechnology company focused on developing immunotherapies to treat cancer and infectious diseases. Founded in 2008, the company leverages its proprietary AI-immunology platform, PIONEERu2122, to identify and develop novel therapies.
Core Business Areas
- Oncology: Developing personalized cancer immunotherapies based on patient-specific tumor mutations and the immune system's response.
- Infectious Diseases: Creating preventative vaccines and immunotherapies for infectious diseases, with a focus on bacterial infections.
Leadership and Structure
The leadership team includes Lars Holm Nielsen (CEO). The company has a board of directors overseeing strategic decisions.
Top Products and Market Share
Key Offerings
- EVX-01: A personalized cancer immunotherapy targeting melanoma and non-small cell lung cancer. Clinical trials are ongoing. Data is not yet available to calculate market share or revenue. Competitors include companies developing personalized cancer vaccines and immunotherapies such as Moderna (MRNA) and BioNTech (BNTX).
- EVX-B1: A vaccine candidate targeting Staphylococcus aureus infections. Clinical trials are ongoing. Data is not yet available to calculate market share or revenue. Competitors include companies developing vaccines for bacterial infections such as Pfizer (PFE) and GSK (GSK).
- EVX-B2: A vaccine candidate against Klebsiella pneumoniae infections. Clinical trials are ongoing. Data is not yet available to calculate market share or revenue. Competitors include companies developing vaccines for bacterial infections such as Pfizer (PFE) and GSK (GSK).
Market Dynamics
Industry Overview
The biotechnology industry is rapidly evolving, with significant advancements in personalized medicine and immunotherapies. Demand for effective cancer treatments and infectious disease vaccines continues to drive growth.
Positioning
Evaxion Biotech AS is positioned as an innovator in AI-driven immunotherapy development. Its PIONEERu2122 platform allows it to potentially identify and develop novel therapies more efficiently than traditional methods.
Total Addressable Market (TAM)
The total addressable market for cancer immunotherapies and infectious disease vaccines is substantial, estimated to be in the tens of billions of dollars annually. Evaxion Biotech AS is aiming to capture a share of this market through its pipeline of clinical-stage candidates.
Upturn SWOT Analysis
Strengths
- Proprietary AI-immunology platform (PIONEERu2122)
- Personalized medicine approach
- Diverse pipeline of clinical-stage candidates
- Experienced management team
Weaknesses
- Limited financial resources compared to larger competitors
- Reliance on clinical trial success
- High risk of drug development failure
- Lack of marketed products
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of the PIONEERu2122 platform to new disease areas
- Positive clinical trial results
- Advancements in AI and immunology
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Failure of clinical trials
- Economic downturn affecting research funding
Competitors and Market Share
Key Competitors
- MRNA
- BNTX
- PFE
- GSK
Competitive Landscape
Evaxion faces strong competition from established pharmaceutical companies with greater resources. Its competitive advantage lies in its AI-driven approach and personalized medicine focus, which could lead to more effective therapies.
Growth Trajectory and Initiatives
Historical Growth: Evaxion Biotech AS's historical growth is primarily defined by its progress in advancing its clinical pipeline. Growth is heavily dependent on positive clinical trial results and partnerships.
Future Projections: Future growth depends on the success of clinical trials and potential regulatory approvals. Analyst estimates vary depending on the perceived likelihood of success. Need to access Analyst report, no URL available.
Recent Initiatives: Recent initiatives include advancing clinical trials for EVX-01, EVX-B1, and EVX-B2.
Summary
Evaxion Biotech AS is a clinical-stage biotech company leveraging AI to develop cancer and infectious disease immunotherapies. While its innovative approach and diverse pipeline are strengths, it faces significant challenges related to clinical trial success, funding, and competition. Positive clinical trial results and strategic partnerships are crucial for its future growth. The company's financial stability is important to monitor given their lack of product revenue.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Various financial data sources for competitor and market data. (General sources used and not a specific URL. The data may not be exact).
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Data is based on available information and may be subject to change. The AI-based rating is subjective and should be interpreted with caution. Market share estimates are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Evaxion Biotech AS
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-02-05 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 46 | Website https://evaxion.ai |
Full time employees 46 | Website https://evaxion.ai | ||
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based cancer vaccine that has completed Phase 1/2a trial to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers, including non-small cell lung cancer. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, a viral vaccine product candidate for targeting Cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.